ESR-1150-CL

ESR-1150-CL is a small molecule drug that acts as an agonist of the adrenergic receptor alpha‑1 (ADRA1). It was initially developed by C.H. Boehringer Sohn AG & Co. KG and later associated with Boehringer Ingelheim. The compound, also known as its hydrochloride salt, has the molecular formula C12H18BrClN4 and CAS number 850715‑60‑5. Its primary mechanism is to stimulate alpha‑1 adrenergic receptors, which are involved in smooth muscle contraction and vascular tone regulation. Clinical development focused on evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects; however, development was discontinued after phase 1 trials[1][2][3][4].

Other names

ESR 1150 CLESR1150 CLESR-1150 CLESR 1150CLESR1150CLESR-1150CLESR-1150 HYDROCHLORIDEESR1150 HYDROCHLORIDEESR 1150 HYDROCHLORIDE